| FTVSX | MVCAX | FTVSX / MVCAX | |
| Total Expense Ratio | 0.85 | 0.99 | 86% |
| Annual Report Gross Expense Ratio | 1.03 | 1.00 | 103% |
| Fund Existence | 8 years | 24 years | - |
| Gain YTD | -1.325 | 4.857 | -27% |
| Front Load | N/A | 6% | - |
| Min. Initial Investment | 100000 | 1000 | 10,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 373M | 17.2B | 2% |
| Annual Yield % from dividends | 1.43 | 0.84 | 170% |
| Returns for 1 year | -1.92 | -7.00 | 27% |
| Returns for 3 years | 24.46 | 20.87 | 117% |
| Returns for 5 years | 70.64 | 44.78 | 158% |
| Returns for 10 years | N/A | 72.73 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FDLS | 34.93 | 0.63 | +1.83% |
| Inspire Fidelis Multi Factor ETF | |||
| PRFZ | 45.99 | 0.56 | +1.24% |
| Invesco RAFI US 1500 Small-Mid ETF | |||
| SNPG | 51.92 | N/A | N/A |
| Xtrackers S&P 500 Growth Scrd & Scrn ETF | |||
| THNR | 23.16 | -0.06 | -0.25% |
| Amplify Weight Loss Drug & Treatment ETF | |||
| BTAL | 15.31 | -0.39 | -2.48% |
| AGF U.S. Market Neutral Anti-Beta | |||